Amarin Corporation PLC
Change company Symbol lookup
Select an option...
AMRN Amarin Corporation PLC
VTN Invesco Trust for New York Investment Grade Municipals
VVR Invesco Senior Income Trust
CLX Clorox Co
SNCY Sun Country Airlines Holdings Inc
NCZ Virtus Convertible & Income Fund II
XPEV Xpeng Inc
PTON Peloton Interactive Inc
PEB Pebblebrook Hotel Trust
VFC VF Corp
Go

Health Care : Biotechnology |
Based in Ireland
Company profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular disease management. The Company operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$1.19
Day's Change
0.04 (3.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.23
Day's Low
1.16
Volume
(Heavy Day)
Volume:
8,254,528

10-day average volume:
2,471,765
8,254,528

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular disease management. The Company operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
1.10x
Price/Book (MRQ)
0.79x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

November 2022
Current Month
9.6M
Previous Month
10.1M
Percent of Float
2.40%
Days to Cover
3.3851 Days

Share Information

AMRN is in a share class of depositary receipt
Float
381.3M
Shares Outstanding
403.8M
Institutions Holding Shares
225
31.56%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in thousands.

Company Officers

  • Per Wold - Olsen
  • Karim MikhailPres.
  • Thomas Charles ReillyCFO
  • Jason MarksExec.VP
  • Aaron D. BergExec.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.